A Loveland man credits an investigational CAR-T cell therapy with improving his condition related to AL amyloidosis, a rare disease characterized by abnormal protein buildup. He participated in a clinical trial at The James Cancer Hospital, although the treatment is not yet widely available.
The treatment improved his condition but did not eliminate the disease. He eventually learned about an investigational CAR-T cell therapy. CAR-T therapy involves collecting a patient's immune cells and modifying them so they can recognize and attack targeted cells. Lomonaco was able to enroll in a clinical trial ... The treatment improved his condition but did not eliminate the disease. He eventually learned about an investigational CAR-T cell therapy. CAR-T therapy involves collecting a patient's immune cells and modifying them so they can recognize and attack targeted cells. Lomonaco was able to enroll in a clinical trial and received the treatment at The James Cancer Hospital at The Ohio State University. He was diagnosed with AL amyloidosis, a rare disease that causes abnormal proteins to build up in the body's organs The treatment Lomonaco received is not yet widely available. He said the clinical trial closed shortly after he underwent the procedure, leaving other people with the disease without the same option. After about a year of tests and visits to several doctors, Michael Lomonaco was diagnosed with AL amyloidosis, a rare disease that causes abnormal proteins to build up in the body's organs. In Lomonaco's case, the disease was affecting his heart. (provided) ... LOVELAND, Ohio (WKRC) - A Loveland man who once struggled to walk from his car to his desk without stopping to catch his breath is now back to exercising after an experimental treatment for a rare disease.
Original title: “Loveland man credits experimental treatment with putting rare disease in remission”